
On Friday, US-based pharmaceutical firm Eli Lilly could announce that the US Food and Drug Administration (FDA) has approved tirzepatide for patients with type 2 diabetes.
With the health authority’s regulatory thumbs-up for the drug, which is dubbed Mounjaro, the US-based firm faces Novo Nordisk and its best-selling type 2 diabetes treatment, Ozempic.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app